Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice.
OBJECTIVE
Antiacid drugs, including omeprazole and ranitidine, were prescribed to Helicobacter pylori-infected subjects in combination with antibiotics during eradication treatment. Several reports suggest that these drugs have additional pharmacological properties, such as antineutrophil, antiapoptotic and antioxidant characteristics. The aim of this work was to study the effects of acid suppressive medication treatment in the H. pylori infection experimental model, focusing on possible additional pharmacological properties.


METHODS
The ability of gastric acid suppression was assessed in pylorus-ligated animals. Gastric H. pylori colonization levels, myeloperoxidase (MPO) acitivity, macroscopic damage, Bax and Bcl-2 expression and DNA damage levels were assessed in C57BL/6-infected mice after treatment for one week with omeprazole (100 mg kg(-1)) or ranitidine (100 mg kg(-1)).


RESULTS
Omeprazole treatment increased bacteria colonization and MPO activity in mice stomachs. Both antiacid drugs efficiently improved macroscopic damage, although only omeprazole restored the expression of the antiapoptotic Bcl-2 protein in gastric mucosa of infected animals.


CONCLUSIONS
Some additional omeprazole-related properties, such as antineutrophil properties, were not observed in H. pylori-infected mice after one week of treatment, suggesting that this property is restricted to in vitro approaches. However, the antiapoptotic activity of omeprazole could be attributed to an ability to modify the protein expression of Bcl-2, decreased by H. pylori infection.
Maróstica
Marta
M
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil.
Arçari
Demetrius Paiva
DP
Bartchewsky
Waldemar
W
Trevisan
Miriam
M
Ribeiro
Marcelo Lima
ML
Pedrazzoli
José
J
Hoehr
Nelci Fenalti
NF
Gambero
Alessandra
A
D000704:Analysis of Variance; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015153:Blotting, Western; D020552:Comet Assay; D004249:DNA Damage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology*; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018709:Statistics, Nonparametric
D000897:Anti-Ulcer Agents; D011899:Ranitidine; D009853:Omeprazole